Maana and Aramco Trading Company Launch AI Application to Optimize Maritime Fleet and Shipping Operations
2.3.2021 17:00:00 EET | Business Wire | Press release
Aramco Trading Company (ATC) and Maana today announced the launch of Fanar, the first Artificial Intelligence (AI)-driven maritime fleet optimization application on Microsoft Azure purpose-built for the oil and gas industry.
Fanar combines the expertise of ATC and the Maana Q knowledge technology. It unifies maritime fleet optimization, planning, management and shipment scheduling on a single platform. The application:
- systematically integrates all data sources, constraints, and business rules
- automatically optimizes schedules across the fleet with a single click
- rapidly processes “what if” scenarios for better insights
- dynamically incorporates historic performance to generate new predictions
Fanar has been tested daily by ATC since June 2020.
“Collaboration between Maana and Microsoft helps us, through Fanar, to drive down costs,” said Ibrahim Q. Al Buainain, President and CEO of Aramco Trading Company. “Fanar enables us to optimize all local decisions across our maritime shipping and logistics workflows.”
Based on any given a set of cargoes and fleet of vessels, Fanar can determine how to ship the cargo in a way that minimizes cost, optimizes fleet utilization and maximizes business value. It continuously computes dynamic criteria such as vessel locations and actuals; terminals and ports status and congestion; bunkering locations, costs and quality; vessel cleaning; time and spot chartering costs; weather; risk of piracy, terrorism or war; risk of labor and social unrest resulting in closures; epidemics; shipping routes; canal fees; charter party specifications; Contracts of Affreightment (COA); commodity prices; special considerations; business rules and more.
“Under the hood of Fanar is the digital twin of ATC’s global maritime operations,” said Babur Ozden, founder and CEO of Maana. “It is the largest digital twin in the world on Microsoft Azure for global maritime shipments of oil and gas, holding the history, present state and future simulations of billions of barrels of petroleum products, thousands of voyages and vessels.”
“Maana is a founding technology member of Energy Core, a global Microsoft initiative dedicated to digital transformation in the energy sector, through the power of artificial intelligence and cloud technologies,” said Darryl Willis, Corporate Vice President of Energy at Microsoft. “Fanar is a great example of how Maana and ATC are using Microsoft Azure for supply chain optimization.”
The Fanar application is available to Azure customers. For more information, please contact Fanar@maana.io
About Aramco Trading Company
Aramco Trading Company (ATC) is a wholly owned subsidiary of Saudi Aramco and is responsible for handling Saudi Aramco’s domestic and international supplies to worldwide markets. ATC’s mission is to integrate Saudi Aramco’s global Downstream assets to maximize profitability while ensuring Saudi Aramco’s systems are optimized and reliably balanced.
About Maana
Maana organizes human expertise, enterprise knowhow and industrial data into digital knowledge to assist subject matter experts at critical operation affecting the global economy.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210302005116/en/
Contact information
Mandi Browning
mandi@maana.io
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom